Suanfarma, at the Core of a Better Life.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 KDMF, $ API Reference Price

1 KDMF
$ API Reference Price

DEVELOPMENTS

24 Drugs in Development

24 Drugs in Development

DIGITAL CONTENT

21 NEWS #PharmaBuzz

media
21 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1903008-80-9, Yh-25448, Gns-1480, Yh25448, Gns1480, Jnj-73841937-aaa

Molecular Formula

C₃₀H₃₄N₈O₃

Molecular Weight

554.6 g/mol

InChI Key

RRMJMHOQSALEJJ-UHFFFAOYSA-N

FDA UNII

4A2Y23XK11

Lazertinib is an orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

1 2D Structure

Lazertinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide

2.1.2 InChI

InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)

2.1.3 InChI Key

RRMJMHOQSALEJJ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC

2.2 Other Identifiers

2.2.1 UNII

4A2Y23XK11

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-

2. Leclaza

3. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide

2.3.2 Depositor-Supplied Synonyms

1. 1903008-80-9

2. Yh-25448

3. Gns-1480

4. Yh25448

5. Gns1480

6. Jnj-73841937-aaa

7. Lazertinib [usan]

8. C-18112003-g

9. N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide

10. 4a2y23xk11

11. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide

12. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-

13. Leclaza

14. Lazertinib [inn]

15. Lazertinib [inn]

16. Lazertinib (yh25448)

17. Lazertinib [who-dd]

18. Unii-4a2y23xk11

19. Chembl4558324

20. Schembl17670400

21. Gtpl10136

22. Bcp30440

23. Ex-a1912

24. Bdbm50555575

25. S8724

26. Who 10587

27. Akos037515597

28. Ccg-270023

29. Lazertinib (yh25448,gns-1480)

30. Yh-25448;gns-1480

31. Ac-36243

32. Bs-15742

33. Compound 73 [wo2016060443a2]

34. Hy-109061

35. Cs-0032992

36. A16827

37. A903188

38. Yh-25448; Yh 25448; Yh25448; Gns-1480; Gns 1480; Gns1480

39. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide

40. N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide

2.4 Create Date

2016-08-06

3 Chemical and Physical Properties

Molecular Formula	C₃₀H₃₄N₈O₃
Molecular Weight	554.6 g/mol
XLogP3	3.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	10
Exact Mass	554.27538698 g/mol
Monoisotopic Mass	554.27538698 g/mol
Topological Polar Surface Area	110 Å²
Heavy Atom Count	41
Formal Charge	0
Complexity	837
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

KDMF

01

Yuhan Corporation

South Korea

Pharma, Lab & Chemical Expo

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Import","activeIngredients":"LAZERTINIB","year":"2021","qtr":"Q1","strtotime":1610649000,"product":"(N.C.V) LAZERTINIB (JNJ-73841937-ZCY) POWDER 1BOTTLE=30G (FOR R&D UNIT ONLY)","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"30","unit":"GMS","unitRateFc":"219.2","totalValueFC":"8254.6","currency":"EUR","unitRateINR":"20123.9","date":"15-Jan-2021","totalValueINR":"603718.11","totalValueInUsd":"8254.6","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2367433","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"LAZERTINIB","year":"2021","qtr":"Q1","strtotime":1611253800,"product":"(N.C.V) (JNJ-73858434-AAA) INTERMEDIATE OF LAZERTINIB (FOR R&D UNIT ONLY)","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"CHINA","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.2","unit":"GMS","unitRateFc":"286","totalValueFC":"70.5","currency":"EUR","unitRateINR":"25782.9","date":"22-Jan-2021","totalValueINR":"5156.58","totalValueInUsd":"70.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2458573","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"LAZERTINIB","year":"2021","qtr":"Q1","strtotime":1613154600,"product":"(N.C.V) LAZERTINIB (JNJ-73841937-ZCY) REF.STD. 2-PROPENAMIDE,N[5-[[4-[4-(DIMETHYLAMINO)METHYL]-3-PHENYL-1H-PYRAZOL-1-YL]","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"KOREA, REPUBLIC OF","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"5","unit":"GMS","unitRateFc":"286","totalValueFC":"1753.9","currency":"EUR","unitRateINR":"25539.8","date":"13-Feb-2021","totalValueINR":"127699","totalValueInUsd":"1753.9","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2753945","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1623954600,"product":"(N.C.V) SELECTVITY BATCH OF LAZERTINIB (JNJ-73841937-ZCY)(R605024 2-PROPENAMIDE,N-[5-[[4-[4-[(DIMETHYLAMINO)METHYL]-3-PH","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.2","unit":"GMS","unitRateFc":"1327","totalValueFC":"324.8","currency":"EUR","unitRateINR":"119430","date":"18-Jun-2021","totalValueINR":"23886","totalValueInUsd":"324.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"4367938","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624645800,"product":"(N.C.V) REF.STD. LAZERTINIB (JNJ-73841937-ZCY)R605024 2-PROPENAMIDE,N-[5-[[4-[4-(DIMETHYLAMINO)METHYL]-3-PHENYL-1H-PYRAZ","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.04","actualQuantity":"40","unit":"GMS","unitRateFc":"286","totalValueFC":"13999.5","currency":"EUR","unitRateINR":"25740","date":"26-Jun-2021","totalValueINR":"1029600","totalValueInUsd":"13999.5","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"4466841","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624645800,"product":"(N.C.V) REF.STD. LAZERTINIB (JNJ-73841937-ZCY)R605024 2-PROPENAMIDE,N-[5-[[4-[4-(DIMETHYLAMINO)METHYL]-3-PHENYL-1H-PYRAZ","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.04","actualQuantity":"40.044","unit":"GMS","unitRateFc":"286","totalValueFC":"14014.9","currency":"EUR","unitRateINR":"25740","date":"26-Jun-2021","totalValueINR":"1030732.2","totalValueInUsd":"14014.9","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"4466841","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630434600,"product":"(N.C.V) LAZERTINIB (JNJ-73841937-ZCY)R605024.REF.STD. 2-PROPENAMIDE,N[5-[[4-[4-[(DIMETHYLAMINO)METHYL]-3-PHENYL-1H-PYRAZ","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"2.5","unit":"GMS","unitRateFc":"286","totalValueFC":"859.3","currency":"EUR","unitRateINR":"25282.4","date":"01-Sep-2021","totalValueINR":"63206","totalValueInUsd":"859.3","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"5268720","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1636050600,"product":"(N.C.V) SELECTIVITY BATCH OF LAZERTINIB JNJ-73848242-AAA,T003901 4-CHLORO-N-(2METHOXY-4-MORPHOLINO-5-NITROPHENYL)PYRIMID","address":"L.B.S. MARG,,MULUND-WEST","city":"MUMBAI,MAHARASHTRA","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.25","unit":"GMS","unitRateFc":"1327","totalValueFC":"392.5","currency":"EUR","unitRateINR":"116908.7","date":"05-Nov-2021","totalValueINR":"29227.18","totalValueInUsd":"392.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"6131290","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"L.B.S. MARG,,MULUND-WEST"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1651084200,"product":"(N.C.V) LAZERTINIB (JNJ-73841937-ZCY (REF.STD.- R605024) 2-PROPENAMIDE, N-[5-[[-4-[4-[(DIMETHYLAMINO)METHYL]-3-PHENYL-1H","address":"L.B.S. MARG,,MULUND-WEST","city":"MUMBAI,MAHARASHTRA","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"286","totalValueFC":"638","currency":"EUR","unitRateINR":"24066.9","date":"28-Apr-2022","totalValueINR":"48133.8","totalValueInUsd":"638","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"8462201","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"L.B.S. MARG,,MULUND-WEST"}]

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

01 Johnson & Johnson Innovative Medicine

U.S.A

PharmaVenue

Not Confirmed

02 Johnson & Johnson Innovative Medicine

U.S.A

PharmaVenue

Not Confirmed

03 Johnson & Johnson

U.S.A

PharmaVenue

Not Confirmed

04 Johnson & Johnson Innovative Medicine

U.S.A

PharmaVenue

Not Confirmed

05 Johnson & Johnson Innovative Medicine

U.S.A

PharmaVenue

Not Confirmed

06 Johnson & Johnson Innovative Medicine

U.S.A

PharmaVenue

Not Confirmed

07 Johnson & Johnson Innovative Medicine

U.S.A

PharmaVenue

Not Confirmed

08 Johnson & Johnson Innovative Medicine

U.S.A

PharmaVenue

Not Confirmed

09 Johnson & Johnson

U.S.A

PharmaVenue

Not Confirmed

10 Johnson & Johnson

U.S.A

PharmaVenue

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Lazertinib Manufacturers

A Lazertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lazertinib, including repackagers and relabelers. The FDA regulates Lazertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lazertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Lazertinib Suppliers

A Lazertinib supplier is an individual or a company that provides Lazertinib active pharmaceutical ingredient (API) or Lazertinib finished formulations upon request. The Lazertinib suppliers may include Lazertinib API manufacturers, exporters, distributors and traders.

Lazertinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Lazertinib Drug Master File in Korea (Lazertinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lazertinib. The MFDS reviews the Lazertinib KDMF as part of the drug registration process and uses the information provided in the Lazertinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Lazertinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lazertinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Lazertinib suppliers with KDMF on PharmaCompass.

Lazertinib GMP

Lazertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Lazertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lazertinib GMP manufacturer or Lazertinib GMP API supplier for your needs.

Lazertinib CoA

A Lazertinib CoA (Certificate of Analysis) is a formal document that attests to Lazertinib's compliance with Lazertinib specifications and serves as a tool for batch-level quality control.

Lazertinib CoA mostly includes findings from lab analyses of a specific batch. For each Lazertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Lazertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Lazertinib EP), Lazertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lazertinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Find Lazertinib manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 KDMF

$ API Reference Price

DEVELOPMENTS

24 Drugs in Development

DIGITAL CONTENT

21 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 317,623

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

01

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

01

02

03

04

05

06

07

08

09

10

Lazertinib Manufacturers

Lazertinib Suppliers

Lazertinib KDMF

Lazertinib GMP

Lazertinib CoA

What are you looking for?